Science 37

Elemental Machines Announces New SVP of Global Sales, Rob Estrella

Retrieved on: 
Tuesday, March 19, 2024
Software, Research, Hardware, Data Management, IOT (Internet of Things), Medical Devices, Technology, Health Technology, Science, Medical Supplies, Other Science, Health, Elemental Machines, Laboratory, Internet of things, Machine, Science 37, Internet, Organization, Elemental, Growth, Retail

Data-driven laboratory and manufacturing operational connectivity pioneer Elemental Machines announced the addition of Rob Estrella as its new SVP of Global Sales.

Key Points: 
  • Data-driven laboratory and manufacturing operational connectivity pioneer Elemental Machines announced the addition of Rob Estrella as its new SVP of Global Sales.
  • Estrella joined Elemental Machines to support their continued and deep commitment to serving the life sciences market and growth of enterprise-level Internet of Things (IoT) technology across laboratory and manufacturing spaces.
  • Elemental Machines is focused on scaling the business to expand into new market categories and facilitating the client journey from incubator to enterprise.
  • Estrella brings 20+ years of commercial expertise, joining Elemental Machines from Science 37 where he was Global Head of Sales.

Contract Research Organization (CRO) Market size to grow by USD 63.35 billion from 2024-2028, Market Growth at 12.61% CAGR expected during the forecast period, Technavio

Retrieved on: 
Wednesday, March 20, 2024
ChromeOS, Software as a service, Science, Chronic condition, Infection, Laboratory, Clinical trial, European, USD, Regulation, Obesity, Biotechnology, Risk, Diabetes, CNS, DSM-IV codes, ROW, Contract research organization, Compound annual growth rate, TB, PPD, Central nervous system disease, Neurology, Medicine, Medication, Clinical, Science 37, Research, Acquisition, Cancer, Drug development, HIV/AIDS, DCT, Growth, Cardiology, Software, Messenger, Behavior, PPD, Inc., Malaria, Lung compliance, Fine chemical

By geography, the global contract research organization (cro) market is segmented into North America, Europe, Asia, and Rest of World (ROW).

Key Points: 
  • By geography, the global contract research organization (cro) market is segmented into North America, Europe, Asia, and Rest of World (ROW).
  • The report provides actionable insights and estimates the contribution of all regions to the growth of the global contract research organization (cro) market.
  • Growth of the Contract Research Organization (CRO) Market industry across North America, Europe, Asia, and Rest of World (ROW)
    Gain instant access to 17,000+ market research reports.
  • The global mRNA synthesis raw material market size is estimated to grow by USD 776.45 million at a CAGR of 4.93% between 2023 and 2028.

eMed completes tender offer for all outstanding shares of Science 37

Retrieved on: 
Tuesday, March 12, 2024
Transfer, Midnight, Science 37, Acquisition, Science, DGCL, USD, Holding company

MIAMI, March 12, 2024 /PRNewswire/ -- eMed, LLC ("eMed") today announced the successful completion of the previously announced tender offer by its wholly-owned subsidiary, Marlin Merger Sub Corporation ("Purchaser"), for all the outstanding shares of common stock, par value $0.0001 per share, of Science 37 Holdings, Inc. (NASDAQ: SNCE) ("Science 37") at a price of USD 5.75 per share.

Key Points: 
  • MIAMI, March 12, 2024 /PRNewswire/ -- eMed, LLC ("eMed") today announced the successful completion of the previously announced tender offer by its wholly-owned subsidiary, Marlin Merger Sub Corporation ("Purchaser"), for all the outstanding shares of common stock, par value $0.0001 per share, of Science 37 Holdings, Inc. (NASDAQ: SNCE) ("Science 37") at a price of USD 5.75 per share.
  • Purchaser has accepted for payment all shares validly tendered and not withdrawn and will promptly pay for such shares.
  • eMed will promptly complete its acquisition of Science 37 through consummation of a merger of Purchaser with and into Science 37 without a vote of the Science 37 stockholders in accordance with Section 251(h) of the Delaware General Corporation Law (the "DGCL").
  • As a result of the merger, Science 37 common stock will cease to be traded on the NASDAQ Capital Market.

SCIENCE 37 HOLDINGS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Science 37 Holdings, Inc. - SNCE

Retrieved on: 
Tuesday, February 27, 2024
Class Action Lawsuit, Professional Services, Legal, KSF, Sale, Science, Science 37

and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Science 37 Holdings, Inc. (NasdaqCM: SNCE) to eMed, LLC.

Key Points: 
  • and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Science 37 Holdings, Inc. (NasdaqCM: SNCE) to eMed, LLC.
  • Under the terms of the proposed transaction, shareholders of Science 37 will receive $5.75 in cash for each share of Science 37 that they own.
  • Please note that the merger is structured as a tender offer, such that time may be of the essence.
  • To learn more about KSF, whose partners include the Former Louisiana Attorney General, visit www.ksfcounsel.com .

Kuehn Law Encourages KAMN, SNCE, KRTX, and BATL Investors to Contact Law Firm

Retrieved on: 
Thursday, February 15, 2024
Battalion, Kaman, Bristol Myers Squibb, Advertising, Human, PLLC, Therapy, Science 37, Science, Security (finance)

NEW YORK, Feb. 15, 2024 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating potential claims related to the below-listed proposed mergers.

Key Points: 
  • NEW YORK, Feb. 15, 2024 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating potential claims related to the below-listed proposed mergers.
  • Kuehn Law may seek additional disclosures or other relief on behalf of the shareholders of these companies.
  • Concerned shareholders are encouraged to contact Justin Kuehn, Esq., at [email protected] or call (833) 672-0814.
  • Kuehn Law covers all case costs and does not charge its investor clients.

eMed commences tender offer for Science 37

Retrieved on: 
Monday, February 12, 2024
Transfer, Acquisition, Letter, Plan, Expiration, Schedule, Telephone, Regulation, Science 37, Science, Agreement, Security (finance)

MIAMI, Feb. 12, 2024 /PRNewswire/ -- eMed, LLC ("eMed") today announced that its wholly-owned subsidiary, Marlin Merger Sub Corporation, a Delaware corporation ("Purchaser"), has commenced a cash tender offer to purchase all the outstanding shares of common stock, par value $0.0001 per share, of Science 37 Holdings, Inc. (NASDAQ: SNCE) ("Science 37") for a price of $5.75 per share (the "Offer").

Key Points: 
  • MIAMI, Feb. 12, 2024 /PRNewswire/ -- eMed, LLC ("eMed") today announced that its wholly-owned subsidiary, Marlin Merger Sub Corporation, a Delaware corporation ("Purchaser"), has commenced a cash tender offer to purchase all the outstanding shares of common stock, par value $0.0001 per share, of Science 37 Holdings, Inc. (NASDAQ: SNCE) ("Science 37") for a price of $5.75 per share (the "Offer").
  • A successful consummation of the tender offer will be followed by a merger to acquire any untendered shares of Science 37 for the same price payable in the tender offer.
  • Science 37 will file today a Solicitation/Recommendation Statement on Schedule 14D-9 (the "Schedule 14D-9") with the SEC, which includes, among other things, the recommendation of the Science 37 board of directors that Science 37's stockholders accept the Offer and tender their shares of Science 37 common stock pursuant to the Offer.
  • This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995, that can generally be identified by words such as "tender offer," "commences," "commenced," "to purchase," "offer," "will," "subject to," "conditions," or similar expressions, or by express or implied discussions regarding the potential outcome of the tender offer for Science 37 being commenced by eMed.

Kuehn Law Encourages SNCE, MGRC, VINE, and KRTX Investors to Contact Law Firm

Retrieved on: 
Monday, January 29, 2024
Bristol Myers Squibb, Therapy, Advertising, Science 37, Science, PLLC, Wine, Human, Security (finance)

NEW YORK, Jan. 29, 2024 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating potential claims related to the below-listed proposed mergers.

Key Points: 
  • NEW YORK, Jan. 29, 2024 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating potential claims related to the below-listed proposed mergers.
  • Kuehn Law may seek additional disclosures or other relief on behalf of the shareholders of these companies.
  • Under the proposed transaction, Science 37 stockholders will receive $5.75 in cash for each share of the Company’s stock.
  • Concerned shareholders are encouraged to contact Justin Kuehn, Esq., at [email protected] or call (833) 672-0814.

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: McGrath RentCorp (Nasdaq – MGRC), Science 37 Holdings, Inc. (Nasdaq – SNCE), Eagle Bulk Shipping Inc. (NYSE - EGLE), Cerevel Therapeutics Holdings, Inc. (Nasdaq – CER

Retrieved on: 
Monday, January 29, 2024
ABBV, Science 37, Science, Brodsky, AbbVie, WSC, Security (finance)

If you own shares and wish to discuss the investigation, contact Jason Brodsky ( [email protected] ) or Marc Ackerman ( [email protected] ) at 855-576-4847.

Key Points: 
  • If you own shares and wish to discuss the investigation, contact Jason Brodsky ( [email protected] ) or Marc Ackerman ( [email protected] ) at 855-576-4847.
  • Under the terms of the agreement, McGrath RentCorp will be acquired by WillScot Mobile Mini Holdings Corp. (“WillScot Mobile Mini”) (Nasdaq - WSC).
  • The transaction values McGrath RentCorp at an enterprise value of $3.8 billion, including approximately $800 million of net debt.
  • Under the terms of the agreement, Eagle Bulk will be acquired by Star Bulk Carriers Corp. (“Star Bulk”) (Nasdaq - SBLK).

Science 37 to be Acquired by eMed, Expanding Access to Patients and Accelerating Enrollment

Retrieved on: 
Monday, January 29, 2024
Patient, Science 37, Science, GAAP, Depreciation, L.L.C, William Blair & Company, Cryptocurrency

The transaction, which has been unanimously approved by Science 37 Board of Directors, is valued at an equity value of approximately $38 million and will be structured as an all-cash tender offer to acquire all outstanding shares of Science 37.

Key Points: 
  • The transaction, which has been unanimously approved by Science 37 Board of Directors, is valued at an equity value of approximately $38 million and will be structured as an all-cash tender offer to acquire all outstanding shares of Science 37.
  • “After an extensive review of opportunities available to Science 37, we believe that eMed provides the greatest value to our stockholders, customers, patients, and employees” said David Coman, Chief Executive Officer at Science 37.
  • Upon completion of the transaction, Science 37 will become a privately held company and shares of Science 37 common stock will no longer be listed on any public market.
  • is serving as exclusive financial advisor to Science 37, and Thompson Hine LLP is serving as legal advisor.

SNCE Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Science 37 Holdings, Inc. Is Fair to Shareholders

Retrieved on: 
Monday, January 29, 2024
Class Action Lawsuit, Other Professional Services, Legal, Professional Services, Fraud, Sale, Advertising, Science 37, Science

Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Science 37 Holdings, Inc. (NASDAQ: SNCE) to eMed, LLC for $5.75 in cash per share is fair to Science 37 shareholders.

Key Points: 
  • Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Science 37 Holdings, Inc. (NASDAQ: SNCE) to eMed, LLC for $5.75 in cash per share is fair to Science 37 shareholders.
  • The investigation concerns whether Science 37 and its board of directors violated the federal securities laws and/or breached their fiduciary duties to shareholders by failing to, among other things: (1) obtain the best possible consideration for Science 37 shareholders; (2) determine whether eMed is underpaying for Science 37; and (3) disclose all material information necessary for Science 37 shareholders to adequately assess and value the merger consideration.
  • On behalf of Science 37 shareholders, Halper Sadeh LLC may seek increased consideration for shareholders, additional disclosures and information concerning the proposed transaction, or other relief and benefits.
  • Halper Sadeh LLC represents investors all over the world who have fallen victim to securities fraud and corporate misconduct.